Physicochemical Properties
| Molecular Formula | C17H30N4O4S |
| Molecular Weight | 386.51 |
| Exact Mass | 386.198 |
| CAS # | 2320274-78-8 |
| Related CAS # | Butyryltimolol;106351-79-5 |
| PubChem CID | 23276806 |
| Appearance | Colorless to light yellow ointment |
| Density | 1.169±0.06 g/cm3(Predicted) |
| Boiling Point | 511.5±50.0 °C(Predicted) |
| LogP | 3.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 11 |
| Heavy Atom Count | 26 |
| Complexity | 430 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | S1N=C(C(=N1)N1CCOCC1)OCC(CNC(C)(C)C)OC(CCC)=O |
| InChi Key | IGJCFKQCZRWRRM-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C17H30N4O4S/c1-5-6-14(22)25-13(11-18-17(2,3)4)12-24-16-15(19-26-20-16)21-7-9-23-10-8-21/h13,18H,5-12H2,1-4H3 |
| Chemical Name | [1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-yl] butanoate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | β adrenergic receptor |
| ln Vitro | When it comes to improving ocular medication absorption, butyryltimolol, a prodrug of tipol, is just as effective as 240-min nasolacrimal blockade[1]. |
| References |
[1]. Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol. Exp Eye Res. 1988 Jan;46(1):59-69. [2]. Ocular and cardiac beta-antagonism by timolol prodrugs, timolol and levobunolol. Curr Eye Res. 1988 Aug;7(8):755-9. |
Solubility Data
| Solubility (In Vitro) | DMSO: ≥ 100 mg/mL (258.73 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (12.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (12.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (12.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5873 mL | 12.9363 mL | 25.8726 mL | |
| 5 mM | 0.5175 mL | 2.5873 mL | 5.1745 mL | |
| 10 mM | 0.2587 mL | 1.2936 mL | 2.5873 mL |